Cabaletta Bio, Inc. — Form 10-Q Summary
Business context and reporting period
Cabaletta Bio is a clinical-stage biotechnology company developing engineered CAAR T-cell therapies for B-cell-mediated autoimmune diseases. The report covers the quarter and nine months ended September 30, 2020. The lead product candidate, DSG3-CAART, was being evaluated in the Phase 1 DesCAARTes trial for mucosal pemphigus vulgaris. The trial began enrolling in June 2020. The company had no commercial products or product revenue.
DSG3-CAART received FDA orphan drug designation in January 2020 and fast track designation in May 2020. Management expected to report acute safety data from the first patient cohort in the first half of 2021. MuSK-CAART was in IND-enabling studies, with an IND submission expected in the second half of 2021.
Financial performance and key metrics
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Research and development expense | $5.7 million in 2020 versus $3.2 million in 2019 | $15.6 million versus $8.6 million |
| General and administrative expense | $2.8 million versus $1.8 million | $8.9 million versus $4.2 million |
| Total operating expenses | $8.4 million versus $5.0 million | $24.5 million versus $12.8 million |
| Net loss | $8.4 million versus $4.7 million | $24.0 million versus $11.5 million |
| Net loss per share | $0.36 loss versus $2.17 loss | $1.09 loss versus $9.34 loss |
| Interest income | $0.02 million versus $0.4 million | $0.5 million versus $1.3 million |
Operating expenses increased primarily because of higher personnel costs, outsourced development services, manufacturing and vector-production activities, clinical-trial start-up costs, and public-company insurance and compliance costs. Interest income declined despite higher invested balances because of lower interest rates.
At September 30, 2020, the company had cash and cash equivalents of $108.7 million, short-term investments of $8.1 million, and long-term investments of $1.3 million, for total cash, cash equivalents and investments of $118.1 million. Accumulated deficit was $57.0 million. Current liabilities were $4.3 million, and the company reported no debt or credit facility.
For the first nine months of 2020, operating activities used $17.6 million of cash, investing activities used $9.9 million, and financing activities used $0.1 million. Cash declined by $27.5 million from $136.2 million at December 31, 2019. Investing outflows primarily reflected purchases of available-for-sale securities and property and equipment.
Material changes versus the prior comparable period
- Research and development expense increased 81% for the quarter and 80% for the nine-month period, driven by manufacturing, development services, personnel, and clinical-trial preparation.
- General and administrative expense increased 53% for the quarter and 113% for the nine-month period, reflecting workforce expansion, higher public-company insurance costs, and professional services.
- Net loss more than doubled for the nine-month period, increasing from $11.5 million to $24.0 million.
- The company invested $11.1 million in available-for-sale securities during the first nine months of 2020 and held $9.4 million of corporate bonds at quarter-end.
- In May and August 2020, the company expanded and extended sponsored research commitments with Penn. The amended research plans require funding through February 2023, with estimated total costs of $11.8 million.
- The company entered into a collaboration and license agreement with Artisan Bio in July 2020 involving gene-editing technology and potential future milestone payments and royalties.
- In August 2020, 1.7 million non-voting common shares were converted into voting common shares. Total shares outstanding at September 30, 2020 were 24.1 million.
Guidance, outlook, risks, contingencies and unusual items
Management expected research and development and general and administrative expenses to increase substantially as clinical development, manufacturing activities, public-company operations, and the product pipeline advance. The company does not expect product revenue for several years, if at all, and expects continuing operating losses.
The filing states that cash, cash equivalents and investments were expected to fund projected operations for at least 12 months following the financial statements. Separately, management stated that the current operating plan supported funding through at least the third quarter of 2022. These estimates depend on assumptions that may prove inaccurate, and additional financing will be required to complete clinical development and support operations.
- The company is highly dependent on Penn for research, clinical development, manufacturing, and technology-transfer activities. Delays, capacity constraints, termination, or unsuccessful technology transfer could delay trials or interrupt supply.
- DSG3-CAART and the broader CAAR T platform remain early-stage and unproven in humans. Clinical, regulatory, manufacturing, enrollment, safety, potency, and durability risks are significant.
- Potential adverse events include cytokine release syndrome, neurotoxicity, off-target effects, immune rejection, and other unexpected toxicities. The FDA requested safety data from Part A of the Phase 1 trial before dosing subjects in Part B; Part B1 dosing was not subject to prior Part A review.
- COVID-19 had not significantly affected the reported financial results, but could delay patient enrollment, manufacturing, clinical-site activity, regulatory interactions, supply chains, and future financing.
- The Penn license requires annual fees, milestone payments that could approach $20.0 million if multiple products are successfully developed and launched, and low-single-digit royalties on product sales. No amounts were due under the license at September 30, 2020.
- The company had committed research, manufacturing, and facility obligations, including up to $537 thousand of manufacturing-related spend over the following six months and an estimated $493 thousand of remaining office lease payments.
- No material litigation was pending, and management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Progress, enrollment, safety findings, dose escalation, and data timing for the DesCAARTes Phase 1 trial.
- Whether the company’s cash runway remains consistent with the stated target of at least the third quarter of 2022 and when additional capital may be required.
- Dependence on Penn, the timing and success of manufacturing technology transfer, and availability of vector and clinical supply.
- Development status and expected IND timing for MuSK-CAART and other pipeline candidates.
- Changes in research commitments, milestone obligations, royalties, and potential payments under the Penn, CHOP, Artisan, and manufacturing arrangements.
- Clinical safety risks specific to CAAR T-cell therapy, including cytokine release syndrome, neurotoxicity, off-target activity, and the effect of treatment without preconditioning.
- Potential dilution from future equity offerings, stock options, and conversion of non-voting shares.